By analysing the data, Xia et al. demonstrated that cisplatin resistance in human ovarian cancer cells was attributed to the regulation of the Keap1-Nrf2-ARE signalling pathway by ovarian cancer cells through the high expression of p62 [67]. Here, NFE2L2 is linked to ovarian carcinoma.